We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Quidel Introduces Savanna True Sample-to-Result Multiplex RT-PCR System at ECCMID 2022

By LabMedica International staff writers
Posted on 22 Apr 2022
Image: Savanna is a multiplex real-time PCR testing platform with simple sample-to-result operation (Photo courtesy of Quidel)
Image: Savanna is a multiplex real-time PCR testing platform with simple sample-to-result operation (Photo courtesy of Quidel)

Quidel (San Diego, CA, USA) introduced the Savanna true sample-to-result multiplex RT-PCR system at ECCMID 2022 which took place for the first time as a hybrid event both online and on-site in Lisbon, Portugal on 23 - 26 April 2022. ESCMID's yearly congress attracts over 14,000 participants. This year, the congress featured a hybrid format to facilitate an onsite and online experience for attendees allowing for remote and face-to-face opportunities to take part in the multifaceted program.

Savanna is a multiplex molecular platform that enables professional customers to analyze up to 12 pathogens or targets, plus controls, from a single assay run in less than 30 minutes. The Savanna system is a fully integrated, sample-to-result automated in-vitro diagnostic platform that performs real-time Polymerization Chain Reaction (PCR) tests by using the Savanna instrument and Savanna assay cartridges. After inserting the assay cartridge, the instrument performs sample and reagent preparation, nucleic acid extraction and amplification, real-time detection of RNA or DNA target sequence, and qualitative or quantitative result interpretation from a variety of sample types. The Savanna system is intended to aid in the diagnosis of related diseases. Quidel has received the CE Mark for its Savanna multiplex molecular analyzer, allowing the company to market and sell the Savanna system in Europe, as well as other countries that accept the CE Mark.

“The Savanna system’s small footprint features integrated sample prep combined with rapid real-time PCR amplification and detection technologies, making it a perfect fit for syndromic testing in hospitals and moderate-complexity labs, with the goal of eventually accessing physician offices, urgent care clinics and other point-of-care locations,” said Douglas Bryant, president and CEO of Quidel Corporation.

Related Links:
Quidel 

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Pipette
Accumax Smart Series

Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more